Overview

A Pilot Open-Label Crossover Bioavailability Study of Celecoxib in Healthy Volunteers

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
A pharmacokinetic study in healthy volunteers to determine the relative bioavailability of three formulations of celecoxib to the approved formulation.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Celecoxib